目的:探討甲亢性心臟病的臨床特點及131碘治療的療效分析。方法:對124例甲心病患者的臨床資料及131碘治療后療效進行回顧性分析。結果:甲亢患者中甲心病發生率為86%,各年齡段均可發病,但40～60歲年齡段較高;甲亢病程越長甲心病發生率越高;甲心病131碘治療的治愈率為879%;甲心病心律失常類型較多,以房顫最為多見; 131碘治療后,各種心律失常復律百分率均大于80%。結論:甲亢患者并發甲心病的發病率與甲亢病程成正相關。早期正確診斷甲心病,可明顯提高甲心病的療效。131碘治療是目前甲心病的最佳治療方法。
【摘要】 目的 探討放射性核素骨顯像和血清前列腺特異抗原（PSA），堿性磷酸酶（ALP），骨特異性堿性磷酸酶（BAP）測定在前列腺癌骨轉移診斷中的價值。 方法 回顧性分析2006年10月-2009年10月50例前列腺癌（PCa）患者骨顯像結果及PSA、ALP、BAP測定結果。 結果 50例Pca患者骨顯像陽性率為70.0%。35例Pca骨轉移患者分布在PSAgt;20.0 ng/mL時占97.1%，BAPgt;20.1 μg/L時占88.6%，ALPgt;130.0 μg/L時占94.3%。血清PSA、ALP、BAP水平隨著放射性核素骨顯像分級的增高而逐步增高，呈高度正相關。 結論 放射性核素骨顯像仍然是目前診斷PCa骨轉移的主要方法；PSA、ALP、BAP亦是重要的輔助診斷指標；PSAgt;20.0 ng/mL時，患者應常規行全身骨顯像檢查。【Abstract】 Objective To explore the clinical value of radionuclide bone scintigraphy and measurements of serum prostate-specific antigen (PSA), alkaline phosphatase (ALP) and bone-specific alkaline phosphatase (BAP) in the diagnosis of bone metastasis in prostate cancer (PCa) patients from October 2006 to October 2009. Methods The results of bone scintigraphy, serum PSA, ALP and BAP were analyzed retrospectively in 50 PCa patients. Results The positive rate of bone scintigraphy was 70.0% in 50 PCa patients. In 35 patients with PCa bone metastasis, 97.1% of them were PSAgt;20.0 ng/mL, 88.6% were BAPgt;20.1 μg/L, and 94.3% were ALPgt;130.0 μg/L. The serum levels of PSA, ALP and BAP were increased step by step along with the advancement of bone metastatic grading from M0 to M3. They were significantly positively correlated. Conclusion Radionuclide bone scintigraphy is a major method in the diagnosis of bone metastasis in PCa patients currently. PSA, ALP and BAP are also important auxiliary diagnostic markers. Patients with the level of PSAgt;20.0 ng/mL should take a routine whole-body examination of bone scintigraphy.